| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 63 | 2023 | 548 | 11.550 |
Why?
|
| Mycobacterium tuberculosis | 65 | 2023 | 426 | 9.800 |
Why?
|
| Interferon-gamma Release Tests | 13 | 2019 | 87 | 4.280 |
Why?
|
| Antitubercular Agents | 22 | 2023 | 318 | 3.130 |
Why?
|
| Tuberculosis, Pulmonary | 20 | 2021 | 247 | 2.790 |
Why?
|
| Latent Tuberculosis | 10 | 2019 | 82 | 2.400 |
Why?
|
| Kidney Transplantation | 21 | 2022 | 755 | 2.330 |
Why?
|
| Bacterial Proteins | 22 | 2017 | 1029 | 2.300 |
Why?
|
| Texas | 49 | 2021 | 6311 | 1.850 |
Why?
|
| Population Surveillance | 9 | 2019 | 627 | 1.720 |
Why?
|
| Antigens, Bacterial | 11 | 2018 | 354 | 1.720 |
Why?
|
| Baths | 3 | 2020 | 16 | 1.530 |
Why?
|
| Anti-Infective Agents, Local | 3 | 2020 | 121 | 1.400 |
Why?
|
| HIV Infections | 21 | 2021 | 2134 | 1.400 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 8 | 2023 | 123 | 1.380 |
Why?
|
| Tuberculin Test | 12 | 2019 | 132 | 1.360 |
Why?
|
| Drug Resistance, Bacterial | 11 | 2018 | 418 | 1.330 |
Why?
|
| Liver Transplantation | 10 | 2023 | 1112 | 1.310 |
Why?
|
| Cross Infection | 6 | 2020 | 544 | 1.300 |
Why?
|
| Enzyme-Linked Immunospot Assay | 3 | 2016 | 33 | 1.250 |
Why?
|
| Health Personnel | 6 | 2019 | 625 | 1.250 |
Why?
|
| Health Status Disparities | 3 | 2020 | 291 | 1.230 |
Why?
|
| Interferon-gamma | 9 | 2018 | 1144 | 1.210 |
Why?
|
| Aortic Valve Insufficiency | 6 | 2023 | 167 | 1.130 |
Why?
|
| Graft Rejection | 13 | 2024 | 834 | 1.100 |
Why?
|
| Hernia, Hiatal | 6 | 2021 | 63 | 1.070 |
Why?
|
| Male | 143 | 2023 | 123000 | 1.060 |
Why?
|
| Humans | 240 | 2024 | 261506 | 1.060 |
Why?
|
| Middle Aged | 112 | 2024 | 86204 | 1.040 |
Why?
|
| Molecular Epidemiology | 12 | 2017 | 246 | 1.030 |
Why?
|
| Adult | 105 | 2024 | 77950 | 1.020 |
Why?
|
| Female | 147 | 2023 | 141928 | 0.990 |
Why?
|
| Chlorhexidine | 3 | 2020 | 88 | 0.930 |
Why?
|
| Risk Factors | 46 | 2023 | 17523 | 0.920 |
Why?
|
| Predictive Value of Tests | 16 | 2023 | 4892 | 0.880 |
Why?
|
| Mycobacterium Infections | 4 | 2009 | 49 | 0.850 |
Why?
|
| Heart Transplantation | 7 | 2024 | 908 | 0.840 |
Why?
|
| Phlebotomy | 2 | 2019 | 26 | 0.840 |
Why?
|
| Polymorphism, Genetic | 7 | 2009 | 1450 | 0.840 |
Why?
|
| Laparoscopy | 10 | 2024 | 1225 | 0.830 |
Why?
|
| Coinfection | 5 | 2019 | 189 | 0.830 |
Why?
|
| Magnetic Resonance Imaging, Cine | 7 | 2023 | 136 | 0.830 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 1054 | 0.820 |
Why?
|
| Hospitals, Public | 1 | 2021 | 64 | 0.800 |
Why?
|
| Patient Readmission | 3 | 2021 | 548 | 0.770 |
Why?
|
| Mass Screening | 7 | 2019 | 1509 | 0.770 |
Why?
|
| Retrospective Studies | 67 | 2024 | 37905 | 0.770 |
Why?
|
| Sputum | 10 | 2018 | 141 | 0.750 |
Why?
|
| Biomedical Research | 2 | 2019 | 806 | 0.750 |
Why?
|
| Bacterial Typing Techniques | 9 | 2013 | 139 | 0.740 |
Why?
|
| Brain Death | 2 | 2021 | 53 | 0.740 |
Why?
|
| Tissue and Organ Procurement | 2 | 2021 | 233 | 0.730 |
Why?
|
| Aged | 68 | 2024 | 70117 | 0.730 |
Why?
|
| Rifampin | 5 | 2021 | 191 | 0.720 |
Why?
|
| Foreign Professional Personnel | 1 | 2019 | 2 | 0.700 |
Why?
|
| Tuberculosis Vaccines | 1 | 2019 | 12 | 0.700 |
Why?
|
| Tissue Donors | 5 | 2021 | 769 | 0.700 |
Why?
|
| Vascular Patency | 1 | 2020 | 218 | 0.690 |
Why?
|
| DNA, Bacterial | 13 | 2015 | 558 | 0.690 |
Why?
|
| Graft Survival | 12 | 2023 | 1062 | 0.680 |
Why?
|
| Hospitals, High-Volume | 1 | 2019 | 77 | 0.680 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2019 | 30 | 0.670 |
Why?
|
| Disease Eradication | 1 | 2019 | 36 | 0.670 |
Why?
|
| Drug Utilization | 1 | 2020 | 179 | 0.660 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2020 | 112 | 0.660 |
Why?
|
| Prevalence | 14 | 2019 | 3260 | 0.660 |
Why?
|
| Angioplasty, Balloon | 1 | 2020 | 183 | 0.650 |
Why?
|
| Lung Transplantation | 5 | 2024 | 359 | 0.650 |
Why?
|
| Contact Tracing | 4 | 2018 | 56 | 0.650 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 93 | 0.640 |
Why?
|
| Adolescent | 39 | 2021 | 31252 | 0.620 |
Why?
|
| Biological Assay | 1 | 2019 | 177 | 0.620 |
Why?
|
| Genotype | 19 | 2019 | 4109 | 0.610 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2019 | 1489 | 0.610 |
Why?
|
| Vascular Diseases | 1 | 2020 | 246 | 0.610 |
Why?
|
| Antibiotics, Antitubercular | 4 | 2021 | 37 | 0.590 |
Why?
|
| Heart-Assist Devices | 6 | 2022 | 1171 | 0.580 |
Why?
|
| Automation, Laboratory | 1 | 2016 | 27 | 0.580 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 289 | 0.580 |
Why?
|
| Critical Care | 2 | 2020 | 770 | 0.570 |
Why?
|
| Young Adult | 32 | 2022 | 21445 | 0.570 |
Why?
|
| Living Donors | 6 | 2022 | 171 | 0.560 |
Why?
|
| Residence Characteristics | 1 | 2019 | 348 | 0.560 |
Why?
|
| Postoperative Complications | 15 | 2024 | 5542 | 0.550 |
Why?
|
| Pancreas Transplantation | 4 | 2020 | 46 | 0.530 |
Why?
|
| Prognosis | 24 | 2021 | 21713 | 0.530 |
Why?
|
| Child, Preschool | 25 | 2019 | 16273 | 0.520 |
Why?
|
| Infant | 19 | 2023 | 13310 | 0.510 |
Why?
|
| Heart Failure | 8 | 2023 | 2516 | 0.510 |
Why?
|
| Immunoenzyme Techniques | 2 | 2007 | 1165 | 0.510 |
Why?
|
| United States | 22 | 2023 | 15433 | 0.510 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2023 | 180 | 0.510 |
Why?
|
| Heart Neoplasms | 3 | 2022 | 214 | 0.510 |
Why?
|
| Transplant Recipients | 7 | 2022 | 324 | 0.500 |
Why?
|
| Prisoners | 3 | 2009 | 34 | 0.500 |
Why?
|
| Clostridium Infections | 1 | 2018 | 252 | 0.490 |
Why?
|
| Intensive Care Units | 4 | 2021 | 717 | 0.480 |
Why?
|
| Comorbidity | 8 | 2021 | 2352 | 0.480 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 610 | 0.470 |
Why?
|
| Streptococcus pyogenes | 7 | 2008 | 119 | 0.470 |
Why?
|
| Feces | 3 | 2018 | 770 | 0.460 |
Why?
|
| Fundoplication | 7 | 2024 | 56 | 0.460 |
Why?
|
| Pain Management | 1 | 2019 | 668 | 0.460 |
Why?
|
| Child | 33 | 2021 | 29154 | 0.460 |
Why?
|
| Microbial Sensitivity Tests | 13 | 2012 | 994 | 0.460 |
Why?
|
| General Surgery | 3 | 2021 | 326 | 0.450 |
Why?
|
| Renal Dialysis | 2 | 2020 | 945 | 0.450 |
Why?
|
| Anti-Bacterial Agents | 4 | 2020 | 2992 | 0.450 |
Why?
|
| Sensitivity and Specificity | 18 | 2021 | 4971 | 0.440 |
Why?
|
| Macrophages | 6 | 2022 | 1304 | 0.440 |
Why?
|
| Incidence | 14 | 2021 | 5673 | 0.440 |
Why?
|
| Urban Population | 2 | 2013 | 269 | 0.430 |
Why?
|
| Polyomavirus Infections | 3 | 2019 | 139 | 0.430 |
Why?
|
| Case-Control Studies | 15 | 2021 | 6100 | 0.430 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2011 | 5539 | 0.420 |
Why?
|
| Motor Vehicles | 1 | 2011 | 8 | 0.420 |
Why?
|
| Disease Outbreaks | 4 | 2017 | 415 | 0.420 |
Why?
|
| Mycobacterium | 4 | 2007 | 56 | 0.410 |
Why?
|
| Logistic Models | 11 | 2018 | 3441 | 0.410 |
Why?
|
| Catalase | 2 | 2009 | 70 | 0.410 |
Why?
|
| BCG Vaccine | 3 | 2018 | 399 | 0.400 |
Why?
|
| Aza Compounds | 1 | 2011 | 25 | 0.400 |
Why?
|
| Isoantibodies | 4 | 2024 | 115 | 0.400 |
Why?
|
| Mycobacterium bovis | 3 | 2019 | 67 | 0.390 |
Why?
|
| ROC Curve | 3 | 2019 | 1183 | 0.390 |
Why?
|
| Time Factors | 15 | 2022 | 12926 | 0.380 |
Why?
|
| Internship and Residency | 5 | 2021 | 1375 | 0.380 |
Why?
|
| Heller Myotomy | 2 | 2021 | 7 | 0.380 |
Why?
|
| Robotic Surgical Procedures | 3 | 2024 | 481 | 0.370 |
Why?
|
| Cardiomyopathies | 3 | 2021 | 610 | 0.370 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 4 | 2011 | 202 | 0.370 |
Why?
|
| Esophageal Achalasia | 2 | 2021 | 36 | 0.370 |
Why?
|
| Renal Insufficiency | 3 | 2022 | 321 | 0.370 |
Why?
|
| Drug Users | 1 | 2009 | 18 | 0.360 |
Why?
|
| Bacteremia | 3 | 2013 | 689 | 0.360 |
Why?
|
| Substance-Related Disorders | 3 | 2019 | 524 | 0.360 |
Why?
|
| DNA Gyrase | 1 | 2009 | 24 | 0.360 |
Why?
|
| Geographic Information Systems | 3 | 2017 | 57 | 0.350 |
Why?
|
| Immunologic Tests | 2 | 2007 | 33 | 0.350 |
Why?
|
| Risk Assessment | 7 | 2023 | 6869 | 0.350 |
Why?
|
| Treatment Outcome | 30 | 2021 | 32848 | 0.350 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 1371 | 0.350 |
Why?
|
| Cross-Sectional Studies | 10 | 2021 | 4314 | 0.350 |
Why?
|
| Soaps | 2 | 2020 | 7 | 0.350 |
Why?
|
| Reproducibility of Results | 8 | 2019 | 6009 | 0.340 |
Why?
|
| Proportional Hazards Models | 12 | 2021 | 4988 | 0.340 |
Why?
|
| Odds Ratio | 5 | 2020 | 2316 | 0.330 |
Why?
|
| Obesity | 4 | 2022 | 2884 | 0.330 |
Why?
|
| Immunosuppressive Agents | 6 | 2020 | 1375 | 0.330 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2008 | 25 | 0.330 |
Why?
|
| Metabolic Syndrome | 2 | 2024 | 353 | 0.330 |
Why?
|
| Cholecalciferol | 2 | 2019 | 46 | 0.320 |
Why?
|
| Staphylococcus aureus | 4 | 2005 | 548 | 0.320 |
Why?
|
| Polymorphism, Restriction Fragment Length | 10 | 2015 | 239 | 0.320 |
Why?
|
| Viremia | 3 | 2019 | 177 | 0.320 |
Why?
|
| BK Virus | 3 | 2019 | 123 | 0.320 |
Why?
|
| Prospective Studies | 19 | 2023 | 12873 | 0.320 |
Why?
|
| Cluster Analysis | 6 | 2017 | 1053 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 4 | 2024 | 1362 | 0.320 |
Why?
|
| Quinolines | 1 | 2011 | 383 | 0.310 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2007 | 11 | 0.310 |
Why?
|
| Kidney Failure, Chronic | 5 | 2021 | 960 | 0.310 |
Why?
|
| Ventricular Function, Left | 5 | 2023 | 603 | 0.310 |
Why?
|
| Antilymphocyte Serum | 2 | 2020 | 228 | 0.300 |
Why?
|
| Tumor Virus Infections | 3 | 2019 | 224 | 0.300 |
Why?
|
| Mycobacterium smegmatis | 2 | 2017 | 8 | 0.300 |
Why?
|
| Minisatellite Repeats | 3 | 2017 | 51 | 0.300 |
Why?
|
| Methicillin Resistance | 2 | 2004 | 147 | 0.300 |
Why?
|
| Enterotoxins | 1 | 2007 | 112 | 0.300 |
Why?
|
| Microscopy, Fluorescence | 3 | 2016 | 769 | 0.290 |
Why?
|
| Isoniazid | 3 | 2016 | 63 | 0.290 |
Why?
|
| Infant, Newborn | 6 | 2019 | 8223 | 0.290 |
Why?
|
| Water Supply | 2 | 2004 | 24 | 0.280 |
Why?
|
| Tuberculosis, Pleural | 1 | 2006 | 11 | 0.280 |
Why?
|
| Multivariate Analysis | 8 | 2019 | 4298 | 0.280 |
Why?
|
| Obesity, Morbid | 3 | 2022 | 224 | 0.270 |
Why?
|
| Interdisciplinary Communication | 2 | 2019 | 280 | 0.270 |
Why?
|
| Mortality | 3 | 2020 | 343 | 0.270 |
Why?
|
| China | 8 | 2019 | 606 | 0.270 |
Why?
|
| Bacterial Toxins | 1 | 2007 | 228 | 0.270 |
Why?
|
| Follow-Up Studies | 18 | 2021 | 14889 | 0.270 |
Why?
|
| Heart Diseases | 2 | 2023 | 732 | 0.270 |
Why?
|
| Age Factors | 5 | 2020 | 5377 | 0.270 |
Why?
|
| Surveys and Questionnaires | 12 | 2020 | 5687 | 0.270 |
Why?
|
| HIV-1 | 3 | 2020 | 653 | 0.260 |
Why?
|
| Alcohol Drinking | 2 | 2019 | 551 | 0.260 |
Why?
|
| Myocardium | 3 | 2021 | 1313 | 0.260 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2018 | 332 | 0.260 |
Why?
|
| Weaning | 2 | 2021 | 45 | 0.260 |
Why?
|
| Bile Duct Neoplasms | 2 | 2021 | 493 | 0.260 |
Why?
|
| Hypertension | 4 | 2021 | 1503 | 0.250 |
Why?
|
| Fluorescent Dyes | 2 | 2019 | 459 | 0.250 |
Why?
|
| Cholangiocarcinoma | 2 | 2021 | 493 | 0.250 |
Why?
|
| Databases, Factual | 4 | 2019 | 2218 | 0.250 |
Why?
|
| Nephrectomy | 4 | 2021 | 779 | 0.250 |
Why?
|
| Thrombosis | 2 | 2022 | 781 | 0.250 |
Why?
|
| Immunoassay | 2 | 2017 | 216 | 0.250 |
Why?
|
| Neurocysticercosis | 3 | 2011 | 33 | 0.250 |
Why?
|
| Interleukin-12 | 2 | 2017 | 253 | 0.240 |
Why?
|
| Mannose-Binding Lectin | 1 | 2004 | 8 | 0.240 |
Why?
|
| Emigrants and Immigrants | 3 | 2015 | 147 | 0.240 |
Why?
|
| Mutation, Missense | 1 | 2009 | 1152 | 0.240 |
Why?
|
| Herniorrhaphy | 3 | 2021 | 169 | 0.240 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2016 | 82 | 0.240 |
Why?
|
| Fibrosis | 6 | 2023 | 793 | 0.230 |
Why?
|
| Hyperinsulinism | 1 | 2024 | 85 | 0.230 |
Why?
|
| Genes, Bacterial | 1 | 2004 | 236 | 0.230 |
Why?
|
| Esophageal Fistula | 1 | 2023 | 27 | 0.230 |
Why?
|
| Interspersed Repetitive Sequences | 2 | 2017 | 33 | 0.230 |
Why?
|
| Area Under Curve | 3 | 2022 | 700 | 0.220 |
Why?
|
| DNA-Directed RNA Polymerases | 3 | 2009 | 97 | 0.220 |
Why?
|
| Plasma Cells | 1 | 2024 | 192 | 0.220 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2020 | 67 | 0.220 |
Why?
|
| Staphylococcal Infections | 3 | 2012 | 672 | 0.220 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 1021 | 0.220 |
Why?
|
| Water Microbiology | 1 | 2002 | 22 | 0.220 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2010 | 317 | 0.220 |
Why?
|
| Islets of Langerhans | 1 | 2024 | 229 | 0.220 |
Why?
|
| Lung Diseases | 2 | 2019 | 717 | 0.220 |
Why?
|
| HLA Antigens | 4 | 2024 | 546 | 0.220 |
Why?
|
| Aged, 80 and over | 19 | 2022 | 29902 | 0.220 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 2 | 2014 | 29 | 0.220 |
Why?
|
| Patient Selection | 2 | 2021 | 2055 | 0.220 |
Why?
|
| Insulin-Secreting Cells | 1 | 2024 | 154 | 0.210 |
Why?
|
| Cicatrix | 2 | 2023 | 208 | 0.210 |
Why?
|
| Faculty | 1 | 2023 | 130 | 0.210 |
Why?
|
| Tuberculosis, Lymph Node | 2 | 2019 | 27 | 0.210 |
Why?
|
| 3' Untranslated Regions | 1 | 2003 | 343 | 0.210 |
Why?
|
| Atrial Fibrillation | 2 | 2023 | 719 | 0.210 |
Why?
|
| Sickle Cell Trait | 1 | 2022 | 31 | 0.210 |
Why?
|
| Solanum tuberosum | 1 | 2022 | 16 | 0.210 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2023 | 435 | 0.210 |
Why?
|
| Aminopeptidases | 2 | 2023 | 34 | 0.210 |
Why?
|
| Factor Xa Inhibitors | 1 | 2022 | 70 | 0.210 |
Why?
|
| Tacrolimus | 2 | 2020 | 335 | 0.210 |
Why?
|
| Agammaglobulinemia | 1 | 2022 | 46 | 0.210 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2021 | 8 | 0.200 |
Why?
|
| Postprandial Period | 1 | 2022 | 85 | 0.200 |
Why?
|
| DNA Transposable Elements | 5 | 2006 | 222 | 0.200 |
Why?
|
| Bacteriological Techniques | 3 | 2017 | 121 | 0.200 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2011 | 4549 | 0.200 |
Why?
|
| Ventricular Remodeling | 4 | 2023 | 248 | 0.200 |
Why?
|
| Sarcoma | 2 | 2022 | 1725 | 0.200 |
Why?
|
| Glomerular Filtration Rate | 5 | 2022 | 602 | 0.200 |
Why?
|
| Interleukin-8 | 1 | 2003 | 519 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2020 | 1033 | 0.190 |
Why?
|
| Research Design | 2 | 2019 | 1544 | 0.190 |
Why?
|
| Kidney Calculi | 1 | 2020 | 40 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 8 | 2011 | 2483 | 0.190 |
Why?
|
| Professional Autonomy | 1 | 2020 | 35 | 0.190 |
Why?
|
| Weight Gain | 2 | 2024 | 464 | 0.190 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2020 | 31 | 0.190 |
Why?
|
| HIV Protease Inhibitors | 1 | 2020 | 72 | 0.190 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2020 | 21 | 0.190 |
Why?
|
| Virulence Factors | 3 | 2022 | 213 | 0.190 |
Why?
|
| Organ Preservation | 1 | 2020 | 43 | 0.190 |
Why?
|
| Blood Glucose | 2 | 2022 | 1244 | 0.190 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 135 | 0.190 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 3 | 2017 | 208 | 0.190 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 1320 | 0.190 |
Why?
|
| Extracellular Fluid | 1 | 2019 | 19 | 0.180 |
Why?
|
| Natriuretic Peptides | 1 | 2019 | 11 | 0.180 |
Why?
|
| Cohort Studies | 9 | 2022 | 9244 | 0.180 |
Why?
|
| Extracellular Matrix | 2 | 2020 | 554 | 0.180 |
Why?
|
| Public Opinion | 1 | 2020 | 83 | 0.180 |
Why?
|
| Interleukin-7 | 2 | 2012 | 95 | 0.180 |
Why?
|
| Fluorometry | 1 | 2019 | 34 | 0.180 |
Why?
|
| Prediabetic State | 1 | 2020 | 57 | 0.180 |
Why?
|
| Pyloromyotomy | 1 | 2019 | 5 | 0.180 |
Why?
|
| Hemorrhage | 2 | 2022 | 712 | 0.180 |
Why?
|
| Anticoagulants | 2 | 2022 | 787 | 0.180 |
Why?
|
| Carcinoid Tumor | 1 | 2022 | 280 | 0.180 |
Why?
|
| alpha-Fetoproteins | 1 | 2021 | 237 | 0.180 |
Why?
|
| Stroke Volume | 4 | 2023 | 577 | 0.180 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2020 | 69 | 0.180 |
Why?
|
| Tuberculosis, Laryngeal | 1 | 2019 | 2 | 0.180 |
Why?
|
| Tuberculosis, Oral | 1 | 2019 | 2 | 0.180 |
Why?
|
| Plasma | 1 | 2020 | 158 | 0.170 |
Why?
|
| Organ Transplantation | 1 | 2022 | 191 | 0.170 |
Why?
|
| Epidemiological Monitoring | 2 | 2018 | 73 | 0.170 |
Why?
|
| Reagent Kits, Diagnostic | 3 | 2019 | 70 | 0.170 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 4320 | 0.170 |
Why?
|
| Vietnam | 1 | 2019 | 56 | 0.170 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 234 | 0.170 |
Why?
|
| Tricuspid Valve | 1 | 2019 | 68 | 0.170 |
Why?
|
| Methacholine Chloride | 1 | 2018 | 29 | 0.170 |
Why?
|
| War Exposure | 1 | 2018 | 8 | 0.170 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 202 | 0.170 |
Why?
|
| Ciprofloxacin | 1 | 2019 | 89 | 0.170 |
Why?
|
| Occupational Health | 1 | 2019 | 95 | 0.160 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 310 | 0.160 |
Why?
|
| False Positive Reactions | 2 | 2016 | 355 | 0.160 |
Why?
|
| Primary Graft Dysfunction | 1 | 2018 | 34 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2019 | 297 | 0.160 |
Why?
|
| Paraganglioma | 1 | 2020 | 170 | 0.160 |
Why?
|
| History, 21st Century | 2 | 2018 | 441 | 0.160 |
Why?
|
| Ascaris lumbricoides | 1 | 2018 | 19 | 0.160 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2018 | 53 | 0.160 |
Why?
|
| Schistosoma haematobium | 1 | 2018 | 19 | 0.160 |
Why?
|
| Teaching | 1 | 2020 | 243 | 0.160 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 222 | 0.160 |
Why?
|
| Datasets as Topic | 1 | 2019 | 181 | 0.160 |
Why?
|
| Streptococcal Infections | 5 | 2008 | 280 | 0.160 |
Why?
|
| Mutation | 8 | 2018 | 15179 | 0.160 |
Why?
|
| Blood Flow Velocity | 1 | 2020 | 475 | 0.160 |
Why?
|
| Colectomy | 2 | 2013 | 288 | 0.160 |
Why?
|
| Specialties, Surgical | 1 | 2020 | 137 | 0.160 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 173 | 0.160 |
Why?
|
| Refugees | 1 | 2018 | 29 | 0.160 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 170 | 0.160 |
Why?
|
| Waiting Lists | 1 | 2020 | 263 | 0.160 |
Why?
|
| Troponin T | 1 | 2019 | 261 | 0.160 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 115 | 0.160 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 2195 | 0.160 |
Why?
|
| Schistosomiasis | 1 | 2018 | 63 | 0.160 |
Why?
|
| Liver Diseases | 1 | 2023 | 574 | 0.160 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2021 | 2027 | 0.160 |
Why?
|
| Shock, Cardiogenic | 1 | 2020 | 228 | 0.160 |
Why?
|
| Health Services | 1 | 2018 | 105 | 0.160 |
Why?
|
| Methylprednisolone | 1 | 2018 | 193 | 0.150 |
Why?
|
| Ascariasis | 1 | 2018 | 65 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 330 | 0.150 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2018 | 87 | 0.150 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2017 | 59 | 0.150 |
Why?
|
| beta-Lactamases | 1 | 2019 | 179 | 0.150 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2017 | 22 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2023 | 620 | 0.150 |
Why?
|
| Deglutition Disorders | 1 | 2021 | 447 | 0.150 |
Why?
|
| Gadolinium | 3 | 2023 | 164 | 0.150 |
Why?
|
| Faculty, Medical | 1 | 2020 | 289 | 0.150 |
Why?
|
| Gastroesophageal Reflux | 1 | 2020 | 334 | 0.150 |
Why?
|
| Fever | 2 | 2018 | 497 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2017 | 673 | 0.150 |
Why?
|
| Communicable Diseases | 1 | 2020 | 193 | 0.150 |
Why?
|
| Aptamers, Nucleotide | 1 | 2017 | 62 | 0.150 |
Why?
|
| Attitude to Health | 1 | 2020 | 465 | 0.150 |
Why?
|
| Ethanol | 1 | 2019 | 264 | 0.150 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2008 | 74 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 275 | 0.150 |
Why?
|
| Learning | 1 | 2020 | 403 | 0.150 |
Why?
|
| Skin Tests | 2 | 2015 | 96 | 0.150 |
Why?
|
| Bradykinin | 1 | 2016 | 79 | 0.150 |
Why?
|
| Riboflavin | 1 | 2016 | 26 | 0.140 |
Why?
|
| Scleroderma, Systemic | 1 | 2018 | 134 | 0.140 |
Why?
|
| Th1 Cells | 1 | 2018 | 250 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2019 | 305 | 0.140 |
Why?
|
| Hyaluronan Receptors | 1 | 2017 | 249 | 0.140 |
Why?
|
| Endothelium, Vascular | 1 | 2021 | 891 | 0.140 |
Why?
|
| Social Class | 2 | 2019 | 310 | 0.140 |
Why?
|
| Schistosoma | 1 | 2016 | 11 | 0.140 |
Why?
|
| Heart Ventricles | 1 | 2021 | 846 | 0.140 |
Why?
|
| Cephalosporins | 2 | 2014 | 148 | 0.140 |
Why?
|
| Pneumococcal Vaccines | 2 | 2008 | 161 | 0.140 |
Why?
|
| Stomach | 1 | 2019 | 387 | 0.140 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 500 | 0.140 |
Why?
|
| Drug Carriers | 1 | 2017 | 327 | 0.140 |
Why?
|
| Heme Oxygenase-1 | 1 | 2016 | 54 | 0.140 |
Why?
|
| Adhesins, Bacterial | 2 | 2007 | 85 | 0.140 |
Why?
|
| Surgical Mesh | 1 | 2017 | 209 | 0.140 |
Why?
|
| School Health Services | 1 | 2016 | 109 | 0.140 |
Why?
|
| Polysaccharides | 2 | 2007 | 197 | 0.130 |
Why?
|
| Neurology | 1 | 2017 | 113 | 0.130 |
Why?
|
| Sepsis | 1 | 2021 | 652 | 0.130 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 716 | 0.130 |
Why?
|
| Fluoroquinolones | 2 | 2019 | 126 | 0.130 |
Why?
|
| Immunologic Memory | 1 | 2017 | 374 | 0.130 |
Why?
|
| Biomarkers | 7 | 2021 | 5047 | 0.130 |
Why?
|
| Mining | 1 | 2015 | 9 | 0.130 |
Why?
|
| Optical Imaging | 1 | 2016 | 157 | 0.130 |
Why?
|
| Socioeconomic Factors | 2 | 2011 | 1225 | 0.130 |
Why?
|
| Contrast Media | 4 | 2023 | 1472 | 0.130 |
Why?
|
| Molecular Sequence Data | 7 | 2014 | 6089 | 0.130 |
Why?
|
| Antigens, Helminth | 1 | 2016 | 178 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 462 | 0.130 |
Why?
|
| Length of Stay | 5 | 2024 | 1900 | 0.130 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 11538 | 0.130 |
Why?
|
| Kidney | 5 | 2021 | 2146 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 1146 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.130 |
Why?
|
| Genetic Loci | 1 | 2017 | 481 | 0.130 |
Why?
|
| Recurrence | 4 | 2018 | 4758 | 0.130 |
Why?
|
| Observer Variation | 1 | 2016 | 671 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 252 | 0.130 |
Why?
|
| Dietary Supplements | 1 | 2019 | 558 | 0.130 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2005 | 568 | 0.130 |
Why?
|
| Ophthalmology | 1 | 2017 | 198 | 0.130 |
Why?
|
| Molecular Typing | 2 | 2012 | 55 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 313 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5319 | 0.120 |
Why?
|
| Antibodies | 2 | 2016 | 838 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 462 | 0.120 |
Why?
|
| Linkage Disequilibrium | 3 | 2005 | 460 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 1217 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 1148 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 2 | 2010 | 778 | 0.120 |
Why?
|
| Transplantation | 1 | 2014 | 56 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2020 | 6207 | 0.120 |
Why?
|
| Travel | 2 | 2013 | 190 | 0.120 |
Why?
|
| Medical Records | 2 | 2013 | 415 | 0.120 |
Why?
|
| Hydrolases | 1 | 2014 | 123 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 6 | 2006 | 3203 | 0.120 |
Why?
|
| Anti-HIV Agents | 3 | 2016 | 350 | 0.120 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 4557 | 0.110 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 4 | 2007 | 128 | 0.110 |
Why?
|
| Nanotechnology | 1 | 2014 | 137 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2005 | 163 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 907 | 0.110 |
Why?
|
| Chaperonins | 3 | 2007 | 27 | 0.110 |
Why?
|
| Survival Rate | 6 | 2022 | 12221 | 0.110 |
Why?
|
| Models, Biological | 1 | 2022 | 3254 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.110 |
Why?
|
| Immunologic Factors | 1 | 2016 | 649 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Population Density | 1 | 2011 | 38 | 0.100 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2012 | 44 | 0.100 |
Why?
|
| Gene Expression Regulation, Bacterial | 4 | 2008 | 192 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 521 | 0.100 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2012 | 72 | 0.100 |
Why?
|
| Endemic Diseases | 1 | 2011 | 67 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2017 | 2803 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 4975 | 0.100 |
Why?
|
| Tuberculoma, Intracranial | 1 | 2011 | 9 | 0.100 |
Why?
|
| Alleles | 4 | 2011 | 2437 | 0.100 |
Why?
|
| Transportation | 1 | 2011 | 50 | 0.100 |
Why?
|
| Ofloxacin | 1 | 2011 | 41 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 1237 | 0.100 |
Why?
|
| Body Mass Index | 4 | 2022 | 2203 | 0.100 |
Why?
|
| Evolution, Molecular | 2 | 2013 | 834 | 0.100 |
Why?
|
| Epidemiologic Methods | 1 | 2011 | 254 | 0.100 |
Why?
|
| Proteinuria | 2 | 2022 | 155 | 0.100 |
Why?
|
| Students | 3 | 2018 | 324 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1048 | 0.100 |
Why?
|
| Animals | 16 | 2024 | 59536 | 0.100 |
Why?
|
| Lighting | 1 | 2010 | 27 | 0.090 |
Why?
|
| Electric Power Supplies | 1 | 2010 | 20 | 0.090 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 2 | 2010 | 31 | 0.090 |
Why?
|
| Clinical Competence | 3 | 2021 | 1270 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2022 | 180 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2020 | 7702 | 0.090 |
Why?
|
| Microscopy | 1 | 2011 | 182 | 0.090 |
Why?
|
| Oropharynx | 2 | 2008 | 74 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 787 | 0.090 |
Why?
|
| Immunization, Passive | 2 | 2020 | 172 | 0.090 |
Why?
|
| Mexico | 3 | 2005 | 259 | 0.090 |
Why?
|
| Iran | 1 | 2009 | 68 | 0.090 |
Why?
|
| Surgical Procedures, Operative | 1 | 2013 | 383 | 0.090 |
Why?
|
| Cells, Cultured | 5 | 2019 | 5637 | 0.090 |
Why?
|
| Reference Values | 2 | 2019 | 1099 | 0.090 |
Why?
|
| GTP-Binding Proteins | 1 | 2011 | 321 | 0.090 |
Why?
|
| RNA, Viral | 3 | 2020 | 671 | 0.090 |
Why?
|
| Preoperative Period | 2 | 2021 | 344 | 0.090 |
Why?
|
| Heart Atria | 2 | 2023 | 352 | 0.090 |
Why?
|
| Macrolides | 2 | 2006 | 62 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2003 | 3341 | 0.090 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 308 | 0.080 |
Why?
|
| Pharynx | 2 | 2007 | 153 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 1879 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2014 | 674 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 761 | 0.080 |
Why?
|
| Meningococcal Vaccines | 1 | 2008 | 31 | 0.080 |
Why?
|
| Bacterial Load | 2 | 2019 | 46 | 0.080 |
Why?
|
| Pharyngitis | 2 | 2005 | 41 | 0.080 |
Why?
|
| Early Diagnosis | 1 | 2009 | 298 | 0.080 |
Why?
|
| Chemokine CXCL6 | 1 | 2008 | 17 | 0.080 |
Why?
|
| Wisconsin | 2 | 2004 | 27 | 0.080 |
Why?
|
| Chemokine CXCL1 | 1 | 2008 | 60 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2018 | 2669 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2007 | 490 | 0.080 |
Why?
|
| DNA Primers | 3 | 2005 | 1399 | 0.080 |
Why?
|
| Radiography | 2 | 2018 | 1904 | 0.080 |
Why?
|
| Virulence | 5 | 2008 | 323 | 0.080 |
Why?
|
| T-Lymphocytes | 4 | 2020 | 3869 | 0.080 |
Why?
|
| Carbohydrate Metabolism | 1 | 2008 | 74 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1945 | 0.080 |
Why?
|
| Propensity Score | 2 | 2021 | 750 | 0.080 |
Why?
|
| Carrier Proteins | 2 | 2007 | 2022 | 0.080 |
Why?
|
| Anus, Imperforate | 1 | 2007 | 10 | 0.080 |
Why?
|
| RNA, Ribosomal, 23S | 1 | 2007 | 26 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2020 | 665 | 0.080 |
Why?
|
| Acinetobacter Infections | 1 | 2007 | 28 | 0.080 |
Why?
|
| Cryptosporidium | 1 | 2007 | 47 | 0.080 |
Why?
|
| Allografts | 2 | 2020 | 650 | 0.080 |
Why?
|
| Trisaccharides | 1 | 2007 | 6 | 0.080 |
Why?
|
| Acinetobacter baumannii | 1 | 2007 | 52 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2013 | 655 | 0.070 |
Why?
|
| Periplasmic Binding Proteins | 1 | 2007 | 37 | 0.070 |
Why?
|
| Fimbriae, Bacterial | 1 | 2007 | 66 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 1011 | 0.070 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2007 | 48 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2023 | 672 | 0.070 |
Why?
|
| Schools | 2 | 2018 | 233 | 0.070 |
Why?
|
| Sentinel Surveillance | 1 | 2006 | 34 | 0.070 |
Why?
|
| Toll-Like Receptors | 1 | 2007 | 174 | 0.070 |
Why?
|
| Fecal Incontinence | 1 | 2007 | 85 | 0.070 |
Why?
|
| Mycobacterium avium Complex | 1 | 2006 | 29 | 0.070 |
Why?
|
| Protozoan Proteins | 1 | 2007 | 114 | 0.070 |
Why?
|
| Pneumonectomy | 2 | 2022 | 831 | 0.070 |
Why?
|
| Risk | 2 | 2021 | 1972 | 0.070 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2006 | 67 | 0.070 |
Why?
|
| Splenic Diseases | 1 | 2006 | 56 | 0.070 |
Why?
|
| Viral Load | 3 | 2019 | 493 | 0.070 |
Why?
|
| Bacterial Adhesion | 1 | 2007 | 147 | 0.070 |
Why?
|
| Suction | 1 | 2006 | 104 | 0.070 |
Why?
|
| Reoperation | 2 | 2023 | 1382 | 0.070 |
Why?
|
| Insulin | 2 | 2024 | 1454 | 0.070 |
Why?
|
| Splenectomy | 1 | 2006 | 158 | 0.070 |
Why?
|
| Peptide Hydrolases | 1 | 2008 | 256 | 0.070 |
Why?
|
| Peptides | 2 | 2017 | 1479 | 0.070 |
Why?
|
| Recombinant Proteins | 2 | 2012 | 2927 | 0.070 |
Why?
|
| Cytokines | 3 | 2022 | 2809 | 0.070 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2005 | 28 | 0.070 |
Why?
|
| Colonic Diseases | 1 | 2006 | 71 | 0.070 |
Why?
|
| Pyrazinamide | 1 | 2005 | 11 | 0.070 |
Why?
|
| Colony Count, Microbial | 2 | 2018 | 149 | 0.070 |
Why?
|
| Amidohydrolases | 1 | 2005 | 25 | 0.070 |
Why?
|
| Biofilms | 1 | 2007 | 199 | 0.070 |
Why?
|
| Thiourea | 1 | 2004 | 18 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 299 | 0.060 |
Why?
|
| Hospitals, Military | 1 | 2004 | 15 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 10035 | 0.060 |
Why?
|
| Pneumonia, Bacterial | 1 | 2006 | 130 | 0.060 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2005 | 122 | 0.060 |
Why?
|
| Abscess | 1 | 2006 | 177 | 0.060 |
Why?
|
| Mice | 7 | 2024 | 34495 | 0.060 |
Why?
|
| Abatacept | 1 | 2024 | 26 | 0.060 |
Why?
|
| Proinsulin | 1 | 2024 | 23 | 0.060 |
Why?
|
| Methionyl Aminopeptidases | 1 | 2023 | 3 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 3 | 2008 | 3101 | 0.060 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 739 | 0.060 |
Why?
|
| Tuberculosis, Cutaneous | 1 | 2003 | 5 | 0.060 |
Why?
|
| Cobalt | 1 | 2023 | 55 | 0.060 |
Why?
|
| Exons | 1 | 2007 | 1328 | 0.060 |
Why?
|
| Osteocalcin | 1 | 2024 | 87 | 0.060 |
Why?
|
| Cation Transport Proteins | 1 | 2005 | 199 | 0.060 |
Why?
|
| Neurosurgical Procedures | 1 | 2009 | 609 | 0.060 |
Why?
|
| Glucagon | 1 | 2024 | 196 | 0.060 |
Why?
|
| Nickel | 1 | 2023 | 44 | 0.060 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2003 | 29 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2004 | 170 | 0.060 |
Why?
|
| Vaccination | 2 | 2008 | 1123 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 3976 | 0.060 |
Why?
|
| Hospitals, Veterans | 1 | 2006 | 397 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2023 | 417 | 0.060 |
Why?
|
| Analysis of Variance | 3 | 2013 | 2307 | 0.060 |
Why?
|
| Nuclear Family | 1 | 2003 | 55 | 0.060 |
Why?
|
| Genetic Variation | 4 | 2005 | 2086 | 0.060 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 182 | 0.060 |
Why?
|
| Lipoproteins, LDL | 1 | 2024 | 163 | 0.060 |
Why?
|
| Family | 3 | 2018 | 736 | 0.060 |
Why?
|
| Peroxidases | 1 | 2003 | 29 | 0.060 |
Why?
|
| Operon | 1 | 2003 | 53 | 0.060 |
Why?
|
| Mass Spectrometry | 2 | 2017 | 702 | 0.060 |
Why?
|
| Repressor Proteins | 2 | 2008 | 1664 | 0.060 |
Why?
|
| Metals | 1 | 2023 | 155 | 0.060 |
Why?
|
| Desensitization, Immunologic | 1 | 2024 | 94 | 0.060 |
Why?
|
| Factor Xa | 1 | 2022 | 26 | 0.050 |
Why?
|
| Hypertrophy | 1 | 2023 | 162 | 0.050 |
Why?
|
| Diastole | 1 | 2023 | 187 | 0.050 |
Why?
|
| Cryptococcosis | 1 | 2003 | 63 | 0.050 |
Why?
|
| Autophagy | 2 | 2020 | 927 | 0.050 |
Why?
|
| Proteasome Inhibitors | 1 | 2024 | 231 | 0.050 |
Why?
|
| Faecalibacterium | 1 | 2022 | 4 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2007 | 1234 | 0.050 |
Why?
|
| Oxidoreductases | 1 | 2003 | 171 | 0.050 |
Why?
|
| Chaperonin 60 | 3 | 2007 | 47 | 0.050 |
Why?
|
| Hemolysis | 1 | 2022 | 127 | 0.050 |
Why?
|
| Rivaroxaban | 1 | 2022 | 59 | 0.050 |
Why?
|
| Diet, High-Fat | 1 | 2024 | 241 | 0.050 |
Why?
|
| Hepatitis | 1 | 2003 | 93 | 0.050 |
Why?
|
| Glycemic Index | 1 | 2022 | 29 | 0.050 |
Why?
|
| Surgical Stapling | 1 | 2022 | 36 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 2314 | 0.050 |
Why?
|
| Cell Line | 3 | 2017 | 5114 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2004 | 285 | 0.050 |
Why?
|
| Probability | 1 | 2004 | 866 | 0.050 |
Why?
|
| DNA Fingerprinting | 3 | 2007 | 167 | 0.050 |
Why?
|
| Phylogeny | 4 | 2005 | 826 | 0.050 |
Why?
|
| Community Health Services | 1 | 2003 | 126 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 13658 | 0.050 |
Why?
|
| Renal Artery | 1 | 2021 | 79 | 0.050 |
Why?
|
| Anastomotic Leak | 1 | 2022 | 71 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2022 | 205 | 0.050 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 86 | 0.050 |
Why?
|
| Equipment Design | 2 | 2017 | 1204 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 163 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2004 | 538 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 3890 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 3639 | 0.050 |
Why?
|
| Cell Survival | 1 | 2007 | 3045 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 6942 | 0.050 |
Why?
|
| Cold Ischemia | 1 | 2020 | 22 | 0.050 |
Why?
|
| Donor Selection | 1 | 2021 | 110 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2007 | 1171 | 0.050 |
Why?
|
| Organophosphates | 1 | 2020 | 41 | 0.050 |
Why?
|
| Operative Time | 1 | 2021 | 217 | 0.050 |
Why?
|
| Postoperative Hemorrhage | 1 | 2022 | 162 | 0.050 |
Why?
|
| Self-Assessment | 1 | 2020 | 96 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2007 | 1682 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2022 | 460 | 0.050 |
Why?
|
| Blood Component Transfusion | 1 | 2020 | 89 | 0.050 |
Why?
|
| Appendectomy | 1 | 2021 | 124 | 0.050 |
Why?
|
| Medical Futility | 1 | 2020 | 54 | 0.050 |
Why?
|
| Vasodilation | 1 | 2021 | 205 | 0.050 |
Why?
|
| Antibodies, Bacterial | 3 | 2008 | 380 | 0.050 |
Why?
|
| Death | 1 | 2021 | 119 | 0.050 |
Why?
|
| Fasting | 1 | 2022 | 349 | 0.050 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2019 | 10 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2021 | 285 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 356 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 324 | 0.040 |
Why?
|
| Azepines | 1 | 2020 | 124 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2019 | 132 | 0.040 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2021 | 334 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 340 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2022 | 337 | 0.040 |
Why?
|
| Vegetables | 1 | 2022 | 325 | 0.040 |
Why?
|
| Aorta | 1 | 2023 | 692 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2019 | 88 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 2020 | 200 | 0.040 |
Why?
|
| Gadolinium DTPA | 1 | 2019 | 172 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 4744 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2020 | 1819 | 0.040 |
Why?
|
| Thrombelastography | 1 | 2020 | 79 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 1323 | 0.040 |
Why?
|
| Perfusion | 1 | 2020 | 293 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 553 | 0.040 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2018 | 16 | 0.040 |
Why?
|
| Triglycerides | 1 | 2021 | 603 | 0.040 |
Why?
|
| Gastrectomy | 1 | 2022 | 451 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2020 | 593 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2023 | 581 | 0.040 |
Why?
|
| Middle East | 1 | 2018 | 46 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2019 | 102 | 0.040 |
Why?
|
| Proteins | 1 | 2007 | 1963 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2021 | 624 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2022 | 1544 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2020 | 314 | 0.040 |
Why?
|
| Disease Progression | 2 | 2020 | 6682 | 0.040 |
Why?
|
| Apoptosis | 3 | 2020 | 7591 | 0.040 |
Why?
|
| Gene Deletion | 3 | 2008 | 1442 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 142 | 0.040 |
Why?
|
| Base Sequence | 4 | 2005 | 4917 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2018 | 78 | 0.040 |
Why?
|
| Calibration | 1 | 2019 | 337 | 0.040 |
Why?
|
| Cholesterol | 1 | 2021 | 658 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2021 | 9180 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2020 | 148 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 484 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 7222 | 0.040 |
Why?
|
| Esophagogastric Junction | 1 | 2021 | 543 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 292 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 97 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2022 | 677 | 0.040 |
Why?
|
| Silicon | 1 | 2017 | 48 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 544 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 499 | 0.040 |
Why?
|
| Poverty | 2 | 2016 | 471 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2018 | 148 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 690 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2018 | 284 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 1085 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 2019 | 223 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2018 | 176 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 235 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 1021 | 0.040 |
Why?
|
| Isocoumarins | 1 | 2016 | 6 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2019 | 2508 | 0.040 |
Why?
|
| Georgia | 1 | 2016 | 53 | 0.040 |
Why?
|
| Maryland | 1 | 2016 | 48 | 0.040 |
Why?
|
| Coumarins | 1 | 2016 | 33 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 1223 | 0.040 |
Why?
|
| RNA, Bacterial | 2 | 2007 | 80 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 10001 | 0.040 |
Why?
|
| Massachusetts | 1 | 2016 | 106 | 0.040 |
Why?
|
| Culture Media | 2 | 2008 | 319 | 0.040 |
Why?
|
| Directly Observed Therapy | 1 | 2016 | 21 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 698 | 0.040 |
Why?
|
| Pneumonia | 1 | 2003 | 751 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2019 | 314 | 0.040 |
Why?
|
| Microbial Viability | 1 | 2016 | 62 | 0.040 |
Why?
|
| Nanomedicine | 1 | 2016 | 54 | 0.040 |
Why?
|
| Global Health | 1 | 2021 | 657 | 0.040 |
Why?
|
| Saliva | 2 | 2008 | 231 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 342 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 541 | 0.040 |
Why?
|
| Phagosomes | 1 | 2016 | 72 | 0.030 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2016 | 50 | 0.030 |
Why?
|
| U937 Cells | 1 | 2016 | 171 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2017 | 144 | 0.030 |
Why?
|
| Triazoles | 1 | 2020 | 617 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 15862 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 1546 | 0.030 |
Why?
|
| Glucose | 1 | 2022 | 1248 | 0.030 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2003 | 962 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2016 | 3033 | 0.030 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2015 | 34 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 482 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2016 | 216 | 0.030 |
Why?
|
| South Africa | 1 | 2015 | 92 | 0.030 |
Why?
|
| Codon | 2 | 2005 | 241 | 0.030 |
Why?
|
| Vascular Calcification | 1 | 2015 | 50 | 0.030 |
Why?
|
| Genetic Markers | 2 | 2011 | 974 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 2292 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 860 | 0.030 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 563 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 4821 | 0.030 |
Why?
|
| Botswana | 1 | 2014 | 87 | 0.030 |
Why?
|
| Photoelectron Spectroscopy | 1 | 2014 | 6 | 0.030 |
Why?
|
| Infection Control | 1 | 2016 | 270 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2016 | 621 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2024 | 5710 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 2843 | 0.030 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 150 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2016 | 403 | 0.030 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 4233 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1440 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2020 | 1987 | 0.030 |
Why?
|
| Lysosomes | 1 | 2016 | 347 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2017 | 644 | 0.030 |
Why?
|
| Pyridines | 1 | 2020 | 1244 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 2588 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2016 | 270 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2014 | 515 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 709 | 0.030 |
Why?
|
| Gold | 1 | 2015 | 270 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 192 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 450 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 1052 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 482 | 0.030 |
Why?
|
| Dialysis | 1 | 2012 | 23 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2017 | 554 | 0.030 |
Why?
|
| Daptomycin | 1 | 2012 | 39 | 0.030 |
Why?
|
| Smoking | 1 | 2021 | 2440 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 2170 | 0.030 |
Why?
|
| Lenses | 1 | 2011 | 14 | 0.030 |
Why?
|
| Miniaturization | 1 | 2011 | 47 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 231 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 915 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 6150 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 1681 | 0.030 |
Why?
|
| Aminoglycosides | 1 | 2012 | 220 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 2083 | 0.020 |
Why?
|
| RNA Stability | 1 | 2012 | 125 | 0.020 |
Why?
|
| Piperazines | 1 | 2020 | 2101 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2018 | 1546 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2016 | 2074 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 3981 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2011 | 120 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2010 | 82 | 0.020 |
Why?
|
| Genome, Human | 1 | 2019 | 1869 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 203 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 306 | 0.020 |
Why?
|
| Urea | 1 | 2012 | 290 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 980 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2010 | 170 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2010 | 105 | 0.020 |
Why?
|
| Vancomycin | 1 | 2012 | 273 | 0.020 |
Why?
|
| Remission Induction | 1 | 2016 | 3569 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 1586 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2003 | 2341 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 7551 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2291 | 0.020 |
Why?
|
| Liver | 1 | 2020 | 2961 | 0.020 |
Why?
|
| Creatinine | 1 | 2012 | 531 | 0.020 |
Why?
|
| Antiparasitic Agents | 1 | 2009 | 39 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2015 | 899 | 0.020 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2008 | 28 | 0.020 |
Why?
|
| HIV Core Protein p24 | 1 | 2008 | 20 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 756 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 980 | 0.020 |
Why?
|
| Streptolysins | 1 | 2008 | 7 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 2315 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 4938 | 0.020 |
Why?
|
| Neutrophil Activation | 1 | 2008 | 34 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 2738 | 0.020 |
Why?
|
| Cell Wall | 1 | 2008 | 46 | 0.020 |
Why?
|
| Enuresis | 1 | 2007 | 5 | 0.020 |
Why?
|
| Social Change | 1 | 2007 | 16 | 0.020 |
Why?
|
| Turkey | 1 | 2007 | 57 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2007 | 40 | 0.020 |
Why?
|
| Aminoacyltransferases | 1 | 2007 | 8 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2008 | 260 | 0.020 |
Why?
|
| Genetic Complementation Test | 1 | 2007 | 125 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 3154 | 0.020 |
Why?
|
| Peritonitis | 1 | 2007 | 89 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2007 | 120 | 0.020 |
Why?
|
| Calorimetry | 1 | 2007 | 62 | 0.020 |
Why?
|
| Maltose | 1 | 2007 | 22 | 0.020 |
Why?
|
| Crohn Disease | 1 | 2011 | 351 | 0.020 |
Why?
|
| Michigan | 1 | 2006 | 67 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2007 | 209 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2007 | 611 | 0.020 |
Why?
|
| Oligosaccharides | 1 | 2007 | 110 | 0.020 |
Why?
|
| Multigene Family | 1 | 2007 | 425 | 0.020 |
Why?
|
| Lung | 1 | 2017 | 3151 | 0.020 |
Why?
|
| North Carolina | 1 | 2006 | 125 | 0.020 |
Why?
|
| Inflammation | 1 | 2016 | 2522 | 0.020 |
Why?
|
| Central America | 1 | 2005 | 29 | 0.020 |
Why?
|
| Cysteine Endopeptidases | 1 | 2007 | 251 | 0.020 |
Why?
|
| Prophages | 1 | 2005 | 6 | 0.020 |
Why?
|
| Clarithromycin | 1 | 2006 | 119 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 6295 | 0.020 |
Why?
|
| Animal Husbandry | 1 | 2005 | 42 | 0.020 |
Why?
|
| Self Concept | 1 | 2007 | 211 | 0.020 |
Why?
|
| Laparotomy | 1 | 2006 | 211 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 461 | 0.020 |
Why?
|
| Emigration and Immigration | 1 | 2005 | 86 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 7226 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2006 | 242 | 0.020 |
Why?
|
| Buffers | 1 | 2004 | 44 | 0.020 |
Why?
|
| Aspartic Acid | 1 | 2005 | 126 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 663 | 0.020 |
Why?
|
| Epithelium | 1 | 2007 | 720 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2005 | 227 | 0.020 |
Why?
|
| Serotyping | 1 | 2004 | 166 | 0.020 |
Why?
|
| Environmental Monitoring | 1 | 2004 | 105 | 0.020 |
Why?
|
| Indians, North American | 1 | 2004 | 87 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2005 | 242 | 0.020 |
Why?
|
| Europe | 1 | 2005 | 649 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2018 | 5270 | 0.010 |
Why?
|
| Serine | 1 | 2005 | 388 | 0.010 |
Why?
|
| Geography | 1 | 2004 | 140 | 0.010 |
Why?
|
| Kinetics | 1 | 2007 | 2049 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2017 | 11965 | 0.010 |
Why?
|
| Catheterization | 1 | 2006 | 410 | 0.010 |
Why?
|
| Mexican Americans | 1 | 2005 | 322 | 0.010 |
Why?
|
| Brazil | 1 | 2003 | 165 | 0.010 |
Why?
|
| Neutrophils | 1 | 2008 | 835 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2003 | 137 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 690 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2006 | 446 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 2003 | 128 | 0.010 |
Why?
|
| HIV | 1 | 2003 | 229 | 0.010 |
Why?
|
| Genome, Bacterial | 1 | 2002 | 200 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2005 | 1471 | 0.010 |
Why?
|
| Species Specificity | 1 | 2002 | 777 | 0.010 |
Why?
|
| Swine | 1 | 2005 | 1541 | 0.010 |
Why?
|
| Caregivers | 1 | 2007 | 677 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 3438 | 0.010 |
Why?
|
| Minority Groups | 1 | 2003 | 322 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2003 | 745 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2007 | 1818 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 3890 | 0.010 |
Why?
|
| Lymphoma | 1 | 2006 | 1467 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 2139 | 0.010 |
Why?
|
| Leukemia | 1 | 2006 | 1635 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 2422 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 4113 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 14289 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2008 | 5159 | 0.010 |
Why?
|
| Quality of Life | 1 | 2007 | 4532 | 0.010 |
Why?
|